ArticleFrontiers in oncology2026
Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to first-line endocrine therapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distant metastatic breast cancer can occur years after initial diagnosis, with choroidal metastasis being a rare but significant manifestation. This case report presents a patient with a history of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) invasive ductal carcinoma (IDC) of the left breast, who developed late choroidal metastasis. The patient underwent systemic therapy with an aromatase inhibitor and cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor leading to regression of choroidal metastases. We also conducted a literature review of similar cases. External beam radiotherapy is the gold standard for management of choroidal metastases. However, it appears that first-line treatment with endocrine therapy and CDK4/6 inhibitors in patients with ER+ and HER2- breast cancer is likely effective for the treatment of choroidal metastases secondary to ER+/HER2- breast cancer and may allow a delay in the use of local invasive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.